5-HT3 receptor antagonists ameliorate fatigue: So much potential, so little knowledge!

Gut

Volumn 54, Issue 8, 2005, Pages 1056-1057

  Barnes, N M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GRANISETRON; METOCLOPRAMIDE; ONDANSETRON; PLACEBO; SEROTONIN 3 ANTAGONIST; TROPISETRON; SEROTONIN ANTAGONIST;

ANTIEMETIC ACTIVITY; BINDING AFFINITY; BINDING SITE; CHRONOPHARMACOLOGY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; FATIGUE; GENE IDENTIFICATION; HEPATITIS C; HUMAN; LOW DRUG DOSE; NAUSEA; NEUROTRANSMISSION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; RECEPTOR BLOCKING; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SEROTONINERGIC TRANSMISSION; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME; VOMITING; ANIMAL; BRAIN LEVEL; NOTE; RAT;

ANIMALS; BRAIN CHEMISTRY; FATIGUE; HUMANS; RATS; SEROTONIN ANTAGONISTS;

EID: 22644437035     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.063545     Document Type: Review

References (25)

1. Hartz AJ, Bentler SE, Brake KA, et al. The effectiveness of citalopram for idiopathic chronic fatigue. J Clin Psychiatry 2003;64:927-35.
2. Wilson WM, Maughan RJ. Evidence for a possible role of 5-nydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, a 5-HT re-uptake inhibitor, reduces the capacity to perform prolonged exercise. Exp Physiol 1992;77:921-4.
3. McGuire J, Ross GL, Price H, et al. Biochemical markers for post-operative fatigue after major surgery. Brain Res Bull 2003;60:125-30.
4. Yamamoto S, Ouchi Y, Onoe H, et al. Reduction of serotonin transporters of patients with chronic fatigue syndrome. NeuroReport 2004;15:2571-4.
5. 11C]WAY-100635. Biol Psychiatry 2005;57:239-46.
6. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999;38:1083-152.
7. 3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study. Gut 2005;54:1169-73.
8. Jones EA. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. Lancet 1999;354:397.
9. Spath M, Welzel D, Farber L. Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists-preliminary results. Scand J Rheumatol 2000;113(suppl):72-7.
10. 3) receptor antagonists: effectiveness of ondansetron. Pain 1995;61:33-7.
11. Muller C, Pongratz S, Pidlich J, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998;10:865-70.
12. 3 receptor antagonists as anti-emetics. Pharm J 1991;246:112-14.
13. 3 receptors. Curr Drug Targets CNS Neurol Disord 2004;3:27-37.
14. 3 recognition sites in human brain tissue. J Neurochem 1989;53:1787-93.
15. 3H]-(S)-zacopride in the rat forebrain. Neuropharmacology 1990;29:1037-45.
16. 3 receptor in the human forebrain. Neuropharmacology 1993;32:1325-32.
17. 3H]metachlorophenylbiguanide. Eur J Pharmacol 1993;243:13-18.
18. 3 receptors in human brain. J Neurol Sci 1996;144:119-27.
19. Davies PA, Pistis M, Hanna MC, et al. The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 1999;397:359-63.
20. Dubin AE, Huvar R, D'Andrea MR, et al. The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit. J Biol Chem 1999;274:30799-810.
21. 3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene 2003;310:101-11.
22. 3 receptors in the CNS: 3B or not 3B? Trends Pharmacol Sci 2003;24:157-60.
23. 3A/3B receptors. Neuropharmacology 2001;41:282-4.
24. 3 receptors. Nature 2003;424:321-4.
25. Jones BJ, Blackburn TP. The medical benefit of 5-HT research. Pharmacol Biochem Behav 2002;71:555-68.